Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 December 2018 | Story Charlene Stanley
Advising pic
Aligning your study field with your career aspirations can be challenging. Academic advising provides solutions.

Over the past few years, institutions of higher learning have experienced an explosive growth in student numbers. Student volumes are often more than campus administrations can effectively deal with. On the students’ side, coming to grips with and transitioning into university and navigating the academic-content processes and technology can be an overwhelming experience – especially for so-called ‘first-generation’ students. Many students often have fixed career dreams, but not a clear knowledge of what they need to get there. This is where academic advising can be a guiding light.

 How Academic Advising works

 Academic advising fosters the development, engagement, and support of students and provides guidance towards academic, personal, and career success. “Through academic advising we basically make sure that students’ career prospects align with their academic programme,” explains Prof Francois Strydom, Senior Director of the Centre for Teaching and Learning (CTL), which houses the UFS Academic Advisement Unit. It is also not only the academic needs of students that are addressed. He describes advising as a ‘hub of the wheel’ that connects students to different departments and services across campus, depending on their needs.

Evolution of Academic Advising

Prof Strydom explains that some type of advising has always existed on university campuses in the form of career counsellors and faculty managers assisting with student queries. But with many institutions virtually doubling in size over the past few years, many students started ‘falling through the cracks’. “There’s been a great need to professionalise this service and to have a clearly defined structure in place with dedicated advisers to assist students quickly and efficiently,” he says. The UFS academic advising team has been playing a leading role in securing a seven-institution collaborative University Capacity Development Grant (UCDG) in 2017 to professionalise the practice in South Africa. 

“We focus on communicating with and serving Kovsie students in ways that really speaks to them, for instance through the Academic Advising Facebook page, email (advising@ufs.ac.za), the electronic magazine (Kovsie Advice), plus face-to-face interactions in the faculties, the Sasol Library in Bloemfontein, and in the TK Mopeli Building on our Qwaqwa Campus,” says Gugu Tiroyabone, who heads the Academic Advisement Unit within CTL. She emphasises that advising is a shared responsibility. “Advisers can never decide for the students but are there to assist them to make informed decisions themselves.”

Data collected from the 1 456 students who utilised continuous academic advising services at the UFS during 2017, has irrefutably shown that these students have a higher probability of passing most of their modules with over 70% – a clear indication that academic advising really works.

Paving a professional path for advisers

Drawing on eight years of ongoing development in academic advising, the UFS piloted the first nationally contextualised Short Learning Programme for advisers in order to guide the development of this practice.

The pilot of the fully accredited Academic Advising Professional Development (AAPD) Short Learning Programme (SLP), which will be presented twice a year, was presented by the CTL early in October 2018 and represented all seven institutions forming part of the UCDG collaboration (UFS, NMU, Wits, UCT, DUT, MUT, and UP).

With the SLP’s ultimate goal to build and cultivate the practice and its practitioners, this national initiative is likely to be one of the enablers for the development and enhancement of student success in South Africa.

 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept